Opus Genetics, a clinical-stage biopharmaceutical company, announced the appointment of Rob Gagnon as Chief Financial Officer.
Rob Gagnon brings over two decades of financial and operational leadership experience in biotech.
His track record includes raising over $2 billion in capital and guiding companies through key strategic milestones.
Experienced CFO
Rob Gagnon has a strong background in capital markets and financial leadership.
Strategic Vision
Opus Genetics aims to advance clinical pipelines and achieve regulatory milestones under the new CFO's guidance.
Biopharmaceutical Focus
Opus Genetics specializes in gene therapies for retinal diseases and small molecule treatments for ophthalmic disorders.
- The appointment of Rob Gagnon as CFO signals Opus Genetics' strategic focus on financial stewardship and operational growth.
- His expertise in guiding companies through high-growth phases aligns with Opus Genetics' goals of delivering innovative therapies.
Rob Gagnon's appointment as CFO at Opus Genetics highlights the company's commitment to financial strength and achieving transformative healthcare outcomes.